MCM
BIOL

Marathon Capital Management’s Biolase, Inc. BIOL Stock Holding History

Marathon Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed -$20K – 193
2020
Q4 		$20K Buy
20
+4
+25% +$3.05K 0.01% 157
2020
Q3 		$11K Buy
16
+8
+100% +$7.5K ﹤0.01% 146
2020
Q2 		$9K Hold
8
– – ﹤0.01% 138
2020
Q1 		$7K Buy
8
+2
+33% +$3.11K ﹤0.01% 120
2019
Q4 		$8K Buy
+6
New +$9.23K ﹤0.01% 142

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DA
DCM Advisors New York $220M AUM 23.37% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marathon Capital Management's BIOL Position: Q1 2021 in Review

Marathon Capital Management sold out of Biolase, Inc. (BIOL) in Q1 2021, closing a stake of 20 shares — an estimated $20K sold.

Marathon Capital Management first reported a position in BIOL in Q4 2019 and held it in 5 quarters. The position peaked at $20K in Q4 2020. 32 funds tracked by Wall St. Rank hold BIOL as of Q1 2021.

  • Marathon Capital Management reported no remaining Biolase, Inc. position as of Q1 2021 after selling out during the quarter.
  • Marathon Capital Management sold 20 Biolase, Inc. shares in Q1 2021, an estimated $20K.
  • Marathon Capital Management first reported a position in Biolase, Inc. in Q4 2019 and held it in 5 quarters.
  • Marathon Capital Management's Biolase, Inc. position peaked at $20K in Q4 2020.
  • 32 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2021.

Based on Marathon Capital Management's 13F filing for Q1 2021, filed 14 May 2021.